Clinical trial
Erlotinib and Gemcitabine in Treating Patients With Metastatic Breast Cancer…
NCT00059852 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00059852 |
|---|---|
| Title | Erlotinib and Gemcitabine in Treating Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline and/or a Taxane |
| Official title | A Phase II Study of OSI-774 (Tarceva) and Gemcitabine for Patients With Metastatic Breast Cancer |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | erlotinib hydrochloride, gemcitabine hydrochloride |
| Enrollment | 61 |
| Start date | Jun 1, 2003 |
| Primary completion | Aug 1, 2006 |
| Completion | Jan 1, 2009 |
| First posted | May 7, 2003 |
| Last update posted | Dec 7, 2016 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: